Does procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate.

TitleDoes procalcitonin have clinical utility in the management of paediatric community-acquired pneumonia? A PRO/CON debate.
Publication TypeJournal Article
Year of Publication2021
AuthorsChiotos K, Gerber JS
JournalJAC Antimicrob Resist
Volume3
Issue4
Paginationdlab153
Date Published2021 Dec
ISSN2632-1823
Abstract

Although the overwhelming majority of community-acquired pneumonia (CAP) in children is caused by viral infections, treatment of CAP is among the most common indications for antibiotic use in children. This is largely driven by the imprecision of clinical diagnostic tools to differentiate viral from bacterial pneumonia and highlights the need for improved approaches to optimizing management of CAP in children. In this issue of JAC-Antimicrobial Resistance, we present a PRO/CON debate that discusses the clinical utility of procalcitonin in children with CAP.

DOI10.1093/jacamr/dlab153
Alternate JournalJAC Antimicrob Resist
PubMed ID34704033
PubMed Central IDPMC8531865
Grant ListK12 HS026393 / HS / AHRQ HHS / United States